

Press release

**Official statement from the European Society for Ceramic Implantology (ESCI)
on the current supply issues affecting ceramic implants**

Zurich, July 30, 2025 – The European Society for Ceramic Implantology (ESCI) notes with concern the current supply shortage of ceramic implants. This problem affects both dentists in their daily practice and patients who require zirconium dioxide implant solutions.

In recent years, demand for zirconium dioxide implants has risen significantly. More and more patients want non-metallic restorations, and numerous clinical studies now confirm the successful use of ceramic implants. The indications have been clearly defined and scientifically sound treatment guidelines have been established to ensure the necessary safety in everyday clinical practice. Ceramic implants have thus increasingly established themselves as an alternative and supplement to titanium implants in dental implantology. However, the resulting increase in demand, combined with interrupted supply chains and limited production capacities, has led to considerable supply bottlenecks in some cases.

In addition, two leading manufacturers of ceramic implants caused confusion in the market: CeramTec Schweiz GmbH discontinued direct sales of the Zeramex XT implant system, and the Straumann Group completely withdrew the renowned and scientifically well-documented PURE ceramic implant from the market.

These developments have caused uncertainty in many practices, with consequences for the treatment of patients who require a non-metallic implant solution. Some common implant and abutment sizes are currently only available to a limited extent or not at all, which can impair the treatment process, therapy safety, and patients' trust in their practitioners and in ceramic implantology. In addition, ceramic implantology as a whole is faced with the critical question of how relevant it really is – when even established systems are simply disappearing from the market or direct sales by the manufacturer are being discontinued.

Users of ceramic implants must be provided with transparent, objective, and reliable information about the actual reasons behind this development. As a neutral and independent professional association for ceramic implantology, the ESCI considers this to be its duty and has therefore issued this statement.

The ESCI is in close contact with manufacturers and suppliers and is monitoring these developments very closely. Particularly noteworthy is the role played by CeramTec Schweiz GmbH, which not only manufactures and distributes the Zeramex® XT implant system, but also produces the CERALOG® PROGRESSIVE-LINE (Camlog AG), NobelPearl® (Nobel BioCare) and SICwhite (SIC invent). Due to supply bottlenecks at the manufacturing company Ceramtec, these brands are also affected by this supply problem through no fault of their own, which could potentially have a negative impact on the trust of end customers and on the brand image of the suppliers.

In view of the increased global demand, the limited availability of raw materials, and the necessary conversion of production processes, CeramTec Schweiz GmbH is currently investing heavily in expanding its production capacities in both implant and prosthetic component manufacturing. This process is not yet complete. However, a noticeable improvement in delivery capacity is expected as

early as fall 2025. The delivery situation should have normalized by the end of 2025. In order to focus on these structural tasks, CeramTec Switzerland GmbH has discontinued direct sales of the Zeramex XT implant.

At almost the same time, another event led to further uncertainty in the market:

Although the PURE implant has extensive long-term data and has proven safe and successful in clinical use, the Straumann Group has decided to discontinue the PURE ceramic implant line for internal and market strategy reasons. The discontinuation of this product line does not mean that the implant has failed or that the company is withdrawing from ceramic implantology. According to its own statements, the company remains committed to the field of ceramic implantology. The Straumann Group currently offers the two-piece Neodent® ceramic system and is pursuing the clear goal of decisively advancing the further development of this promising segment. The focus is increasingly on optimizing existing manufacturing processes and further developing innovative production technologies.

The commitment of both the Straumann Group and CeramTech Schweiz GmbH remains unchanged: to further develop ceramic implants as an integral part of modern, non-metallic implantology and to rethink them in a future-oriented way.

What does all this mean for users?

The current "trough" in ceramic implantology has not been caused by a lack of market demand, poor product quality or bad experiences, but by exactly the opposite:

Too much demand too quickly coincided with supply bottlenecks for raw materials, unprepared production capacities, and internal company restructuring. The high relevance of ceramic implants has been recognized, and the focus is now on further quality improvements. To achieve this, cuts had to be made first in order to then be able to reposition the company for the future.

ESCI will continue to monitor these developments with interest—it will be exciting to see what happens next! Overall, however, this is positive news for all practitioners and affected patients in the medium term.

However, the ESCI also points out that the discontinuation of scientifically proven and clinically established product lines, as well as serious supply bottlenecks, could seriously undermine and even damage the justified increased confidence in ceramic implantology as a whole. This makes it all the more important that the ongoing commitment to this treatment concept and the announced further development of innovative manufacturing processes are not only consistently pursued and promises kept, but also communicated openly and transparently.

The ESCI therefore welcomes the measures taken by manufacturers and suppliers to remedy the current difficult situation and supports all efforts to sustainably strengthen and establish ceramic implantology in practice and science.

ESCI also actively supports its members—both in communicating with patients and in selecting well-founded alternative treatment concepts during the transition period. In the event of acute supply shortages and associated emergencies, the ESCI office is happy to assist its members.

We therefore recommend that during the transition period until the affected products are fully available (, Zeramex XT, Nobel Pearl, Ceralog Progressive Line, SICwhite), you:

1. Inform your patients about the current situation. This statement can be used as an objective source of information. You can also find this statement on the ESCI website at . www.esci-online.com/statements
2. Currently, only implant the affected ceramic implants if all components required for the prosthetic restoration are already available in your practice or will be available in the foreseeable future. Alternatively, the patient should have been fully informed about the current delivery situation and have given their express consent.
3. If not all the necessary components are available, check whether the procedure can be safely and sensibly postponed until the complete restoration can be guaranteed.
4. Please inform the ESCI if you or your partner laboratory have stocks of implants and abutments that are not expected to be needed (Zeramex XT, Nobel Pearl, Ceralog Progressive Line, SICwhite). Please also forward this request to your partner laboratory.
5. Please contact ESCI if you urgently need implants and components. Please state the reason for the urgency.
6. Where possible, ESCI will coordinate and arrange a collegial exchange of components for its members, involving the respective companies. ESCI does not act as a distributor in this regard.
7. Contact: info@esci-online.com

The ESCI board is confident that the supply situation will indeed improve significantly in fall 2025 and that the 3rd European Congress for Ceramic Implant Dentistry on September 25-27, 2025, will herald a "restart" for ceramic implantology. Find out more and register at www.esci-online.com/congress

ESCI will continue to work hard to make sure there's a stable supply of high-quality metal-free implant systems – for a successful and healthy future for everyone involved.

Kilchberg, August 13, 2025

The ESCI Executive Board

Dr. Jens Tartsch **PD Dr. Stefan Röhling**

President of ESCI Vice President ESCI

Dr. Frank Maier, M.Sc.

Member of the Executive Board

Prof. Andre Chen

Member of the Executive Board

The Scientific Advisory Board of ESCI

Prof. Jerome Chevalier

Prof. Corrado Picconi

PD Dr. Michael Gahlert

Prof. Jens Fischer

Prof. Mutlu Özcan

Prof. Werner Zechner

Prof. Michael Payer,